• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Illumina

Illumina

Illumina Inc ILMN

Last Price$166.35Day Change (%)-0.04%
Open Price$165.97Day Change ($)-0.07
Day Range163.11–166.6352-Week Range127.10–220.86

As of Fri 7/29/2016 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016

    Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016

  2. Global Genetic Testing Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Roche Diagnostics, Myriad Genetics - Research and Markets

    Global Genetic Testing Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Roche Diagnostics, Myriad Genetics - Research and Markets

  3. UPDATE: Why knowing your genetic data can be a tricky proposition

    UPDATE: Why knowing your genetic data can be a tricky proposition

  4. Tuttle Tactical Management Weekly Market Notes

    Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...

  5. Leader in Genomic Sequencing Illuminates the Way

    Continued technology advancements and market expansion support Illumina's narrow moat.

  6. Nucleic Acid Purification Market 2016: New Life Science Dashboard™ from Percepta observes decreased number of end-users but projects unit growth in the dynamic $1 Billion market in North America and ...

    Nucleic Acid Purification Market 2016: New Life Science Dashboard™ from Percepta observes decreased number of end-users but projects unit growth in the dynamic $1 Billion market in North America and Europe

  7. 3 Big Moat Rating Changes From 2014

    Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.

  8. A Shift in Health-Care M&A Activity

    Recent deals have been driven more by tax strategies than therapeutic synergies.

  9. Top 10 Holdings of Our Best-Performing Ultimate Stock-Pickers

    While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.

  10. Which Funds Own My Stock?

    Ownership data provide a look at who else owns the company.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.